CER Daily Newsfeed

Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study

(1/8, HealthDay News) reports “For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.” Full

Comparative Efficacy Studies: Where Are We Now?

(1/8, GaBi Online) reports “...As more biologicals lose exclusivity, regulators are encouraged to simplify and accelerate biosimilar development to enhance competition and improve access to essential medicines. [Professor Pekka Kurki, a Clinical Immunology Professor at University of Helsinki, Finland,] notes that coordinated efforts among regulatory agencies can facilitate better alignment on the necessity of comparative efficacy studies, ultimately benefiting public health and expanding treatment options for patients.” Full

Leveraging Artificial Intelligence Alongside RWE/RWD

(1/8, Andy Studna, Applied Clinical Trials) “In a recent video interview with Applied Clinical Trials, Sujay Jadhav, CEO of Verana Health, discussed potential advancements the clinical research industry could see in 2025. Jadhav highlighted how unstructured data like physician notes and imaging data can be leveraged to improve disease identification and progression tracking. He also talked synthetic control arms and how they can replace expensive non-treatment arms, enhancing trial efficiency.” View Video

Revamped Drug Reimbursement Reviews Expected In Canada Soon

(1/8, Neena Brizmohun, Pink Sheet) reports “...If all goes to plan, improvements the national health technology assessment agency wants to make to its drug review procedures – including the tailored, complex and accelerated access reviews – could become effective for applications received in the first half of 2025.” Subscription Required